Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease

Colloids and Surfaces B: Biointerfaces

Volumn 147, Issue , 2016, Pages 475-491

  Shao, Mei ^a   Hussain, Zahid ^b   Thu, Hnin Ei ^c   Khan, Shahzeb ^d   Katas, Haliza ^e   Ahmed, Tarek A ^f   Tripathy, Minaketan ^b   Leng, Jing ^a   Qin, Hua Li ^a   Bukhari, Syed Nasir Abbas ^a  

^a WUHAN UNIVERSITY OF TECHNOLOGY   (China)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^c DEPARTMENT OF PHARMACOLOGY   (Malaysia)

^d UNIVERSITY OF MALAKAND   (Pakistan)

^e UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^f KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Advanced nanocarrier based therapies; Atopic dermatitis; Ethosomes; Liposomes; Nanoemulsion; Polymeric nanoparticles; Solid lipid nanoparticles

Indexed keywords

DERMATITIS; LIPOSOMES; NANOPARTICLES; POLYMERS;

ATOPIC DERMATITIS; ETHOSOMES; NANOCARRIERS; NANOEMULSION; POLYMERIC NANOPARTICLES; SOLID LIPID NANOPARTICLE (SLN);

FUNCTIONAL POLYMERS;

CALCINEURIN INHIBITOR; CALCIPOTRIOL; CORTICOSTEROID; ETHOSOME; GAMMA INTERFERON; HYDROGEL NANOPARTICLE; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LIPOSOME; NANOCARRIER; NANOPARTICLE; OREGONIN; SOLID LIPID NANOPARTICLE; TAXIFOLIN; UNCLASSIFIED DRUG; DRUG CARRIER;

ATOPIC DERMATITIS; ATOPY; CYTOKINE PRODUCTION; DIET THERAPY; DRUG DELIVERY SYSTEM; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; LIPOSOMAL DELIVERY; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; SKIN CARE; SKIN PERMEABILITY; CHEMISTRY; DERMATITIS, ATOPIC; DISEASE MANAGEMENT; NANOMEDICINE; TRENDS;

DERMATITIS, ATOPIC; DISEASE MANAGEMENT; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE;

EID: 84984782982     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2016.08.027     Document Type: Review

References (162)

1. [1] Eichenfield, L.F., Hanifin, J.M., Luger, T.A., Stevens, S.R., Pride, H.B., Consensus conference on pediatric atopic dermatitis. J. Am. Acad. Dermatol. 49 (2003), 1088–1095.
2. [2] Bieber, T., Atopic dermatitis. New Engl. J. Med. 358:14 (2008), 1483–1494.
3. [3] Grillo, M., Ng, M., Gassner, L., Pediatric atopic eczema: the impact of an educational intervention. Pediatr. Dermatol. 23:5 (2006), 428–436.
4. [4] Schultz-Larsen, F., Hanifin, J., Epidemiology of atopic dermatitis. Immunol. Allergy Clin. 22 (2002), 1–24.
5. [5] Hanifin, J.M., Reed, M.L., A population-based survey of eczema prevalence in the United States. Dermatitis 18 (2007), 82–91.
6. [6] Tay, Y.K., Kong, K.H., Khoo, L., The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br. J. Dermatol. 146 (2002), 101–106.
7. [7] Möhrenschlager, M., Darsow, U., Schnopp, C., Ring, J., Atopic eczema: what's new?. J. Eur. Acad. Dermatol. Venereol. 20 (2006), 503–513.
8. [8] Tamura, K., Suzuki, M., Arakawa, H., Tokuyama, K., Morikawa, A., Linkage and association studies of STAT6 gene polymorphisms and allergic diseases. Int. Arch. Allergy Immunol. 131 (2003), 33–38.
9. [9] LipozenciĆ, J., Wolf, R., Atopic dermatitis: an update and review of the literature. Dermatol. Clin. 25:4 (2007), 605–612.
10. [10] Irvine, A., Mclean, I., Breaking the sound barrier: filaggrin is a major gene for atopic dermatitis. J. Invest. Dermatol. 126 (2006), 1200–1202.
11. [11] Elias, P.M., Skin barrier function. Curr. Allergy Asthma Rep. 8:4 (2008), 299–305.
12. [12] Cork, M.J., Danby, S.G., Vasilopoulos, Y., Epidermal barrier dysfunction in atopic dermatitis. J. Invest. Dermatol. 1299:8 (2009), 1892–1908.
13. [13] Lugovic, L., Lipozencic, J., JakicRazumovic, J., Prominent involvement of activated Th1subset of Tcells and increased expression of receptor for IFN-γ on keratinocytes in atopic dermatitis acute skin lesions. Int. Arch. Allergy Immunol. 137 (2005), 125–133.
14. [14] Toda, M., Leung, D.Y., Molet, S., Boguniewicz, M., Taha, R., Christodoulopoulos, P., Fukuda, T., Elias, J.A., Hamid, Q.A., Polarized in vivo expression of IL11 and IL17 between acute and chronic skin lesions. J. Allergy Clin. Immunol. 111 (2003), 875–881.
15. [15] Echigo, T., Hasegawa, M., Shimada, Y., Takehara, K., Sato, S., Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. J. Allergy Clin. Immunol. 113 (2004), 940–948.
16. [16] Sator, P.G., Schmidt, J.B., Honigsmann, H., Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J. Am. Acad. Dermatol. 48 (2003), 352–358.
17. [17] Nagelkerken, L., Verzaal, P., Lagerweij, T., Persoon-Deen, C., Berbee, J.F., Prens, E.P., Havekes, L.M., Oranje, A.P., Development of atopic dermatitis in mice transgenic for human apolipoprotein C1. J. Invest. Dermatol. 128:5 (2008), 165–172.
18. [18] Cork, M.J., Danby, S.G., Vasilopoulos, Y., Epidermal barrier dysfunction in atopic dermatitis. J. Invest. Dermatol. 1299:8 (2009), 1892–1908.
19. [19] Moser, K., Kriwet, K., Naik, A., Kalia, Y.N., Guy, R.H., Passive skin penetration enhancement and its quantification in vitro. Eur. J. Pharm. Biopharm. 52:2 (2001), 103–112.
20. [20] Benson, H.A., Transdermal drug delivery: penetration enhancement techniques. Curr. Drug Deliv. 2:1 (2005), 23–33.
21. [21] Brown, M.B., Martin, G.P., Jones, S.A., Akomeah, F.K., Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 13:3 (2006), 175–187.
22. [22] El Maghraby, G.M., Williams, A.C., Barry, B.W., Can drug-bearing liposomes penetrate intact skin?. J. Pharm. Pharmacol. 58:4 (2006), 415–429.
23. [23] Romero, E.L., Morilla, M.J., Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations. Int. J. Nanomed. 8 (2013), 3171–3186.
24. [24] Elsayed, M.M., Abdallah, O.Y., Naggar, V.F., et al. Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen. Pharmazie 62:2 (2007), 133–137.
25. [25] Benson, H.A., Transfersomes for transdermal drug delivery. Expert Opin. Drug Deliv. 3:6 (2006), 727–737.
26. [26] Touitou, E., Godin, B., Weiss, C., Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug Dev. Res. 50:3 (2000), 406–415.
27. [27] Godin, B., Touitou, E., Mechanism of bacitracin permeation enhancement through the skin and cellular membranes from an ethosomal carrier. J. Control. Release 94:2–3 (2004), 365–379.
28. [28] Zhu, X., Li, F., Peng, X., Zeng, K., Formulation and evaluation of lidocaine base ethosomes for transdermal delivery. Anesth. Analg. 117:2 (2013), 352–357.
29. [29] Mandawgade, S.D., Patravale, V.B., Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int. J. Pharm. 363:1–2 (2008), 132–138.
30. [30] Pople, P.V., Singh, K.K., Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis-part II: in vivo assessment of dermatopharmacokinetics, biodistribution and efficacy. Int. J. Pharm. 15:434 (2012), 70–79.
31. [31] Kim, S.T., Jang, D.J., Kim, J.H., Park, J.Y., Lim, J.S., Lee, S.Y., Lee, K.M., Lim, S.J., Kim, C.K., Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Pharmazie 64:8 (2009), 510–514.
32. [32] Heuschkel, S., Goebel, A., Neubert, R.H., Microemulsions–modern colloidal carrier for dermal and transdermal drug delivery. J. Pharm. Sci. 97:2 (2008), 603–631.
33. [33] Khurana, S., Jain, N.K., Bedi, P.M., Nanoemulsion based gel for transdermal delivery of meloxicam: physico-chemical, mechanistic investigation. Life Sci. 14:92 (2013), 383–392.
34. [34] Hussain, Z., Katas, H., Amin, M.C., Kumulosasi, E., Sahudin, S., Antidermatitic perspective of hydrocortisone as chitosan nanocarriers: an ex vivo and In vivo assessment using an NC/Nga mouse model. J. Pharm. Sci. 102:3 (2013), 1063–1075.
35. [35] Lademann, J., Richter, H., Teichmann, A., Otberg, N., Blume-Peytavi, U., Luengo, J., Weiss, B., Schaefer, U.F., Lehr, C.M., Wepf, R., Sterry, W., Nanoparticles–an efficient carrier for drug delivery into the hair follicles. Eur. J. Pharm. Biopharm. 66:2 (2007), 159–164.
36. [36] Colonna, C., Conti, B., Perugini, P., Pavanetto, F., Modena, T., Dorati, R., Iadarola, P., Genta, I., Ex vivo evaluation of prolidase loaded chitosan nanoparticles for the enzyme replacement therapy. Eur. J. Pharm. Biopharm. 70:1 (2008), 58–65.
37. [37] Lee, P.W., Peng, S.F., Su, C.J., Mi, F.L., Chen, H.L., Wei, M.C., Lin, H.J., Sung, H.W., The use of biodegradable polymeric nanoparticles in combination with a low-pressure gene gun for transdermal DNA delivery. Biomaterials 29:6 (2008), 742–751.
38. [38] Li, G., Fan, Y., Fan, C., Li, X., Wang, X., Li, M., Liu, Y., Tacrolimus-loaded ethosomes: physicochemical characterization and in vivo evaluation. Eur. J. Pharm. Biopharm. 82:1 (2012), 49–57.
39. [39] Goindi, S., Dhatt, B., Kaur, A., Ethosomes-based topical delivery system of antihistaminic drug for treatment of skin allergies. J. Microencapsul. 31:7 (2014), 716–724.
40. [40] Goindi, S., Kumar, G., Kaur, A., Novel flexible vesicles based topical formulation of levocetirizine: in vivo evaluation using oxazolone-induced atopic dermatitis in murine model. J. Liposome Res. 24:3 (2014), 249–257.
41. [41] de la Rica, Roberto, Aili, Daniel, Stevens, M. Molly, Enzyme-responsive nanoparticles for drug release and diagnostics. Adv. Drug Deliv. Rev. 64:11 (2012), 967–978.
42. [42] Xu, Xuewei, Flores, D. Joels, McCormick, L. Charles, Reversible imine shell cross-Linked micelles from aqueous RAFT-synthesized thermoresponsive triblock copolymers as potential nanocarriers for pH-triggered drug release. Macromolecules 44:6 (2011), 1327–1334.
43. [43] Singh, Neetu, Karambelkar, Amrita, Gu, Luo, Lin, Kevin, Miller, Jordan S., Chen, Christopher S., Sailor, Michael J., Bhatia, Sangeeta N., Bioresponsive mesoporous silica nanoparticles for triggered drug release. J. Am. Chem. Soc. 133:49 (2011), 19582–19585.
44. [44] R. Beumer, C. Chen, H. Gutzwiller, 2008. Topical compositions comprising nanoparticles of an isoflavone US Patent Application, 20080311209.
45. [45] P. Dmowski, G.T. Dipiano, 2008. Topical administration of danazol. US Patent Application, 20080153789.
46. [46] Agnieszka, Z., Wilczewska, Katarzyna, Niemirowicz, Karolina H., Markiewicz, Halina Car., Nanoparticles as drug delivery systems. Pharmacol. Rep. 64 (2012), 1020–1037.
47. [47] Proksch, E., Brandner, J.M., Jensen, J.-M., The skin: an indispensable barrier. Exp. Dermatol. 17:12 (2008), 1063–1072.
48. [48] Madison, K.C., "Barrier function of the skin: “la raison d'être” of the epidermis". J. Invest. Dermatol. 121:2 (2003), 231–241.
49. [51] Smith, S.D., Hong, E., Fearns, S., Blaszczynski, A., Fischer, G., Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Australas. J. Dermatol. 51 (2010), 168–174.
50. [52] Bath-Hextall, F., Delamere, F.M., Williams, H.C., Dietary exclusions for improving established atopic eczema in adults and children: systematic review. Allergy 64:2 (2009), 258–264.
51. [53] Snijders, B.E., Thijs, C., van Ree, R., van den Brandt, P.A., Age at first introduction of cow milk products and other food products in relation to infant atopic manifestations in the first 2 years of life: the KOALA birth cohort study. Pediatrics, 122(1), 2008, E115E122.
52. [54] Gdalevich, M., Mimouni, D., David, M., Mimouni, M., Breastfeeding and the onset of atopic dermatitis in childhood: a systematic review and meta-analysis of prospective studies. J. Am. Acad. Dermatol. 45 (2001), 520–527.
53. [55] Laubereau, B., Brockow, I., Zirngibl, A., Koletzko, S., Gruebl, A., von Berg, A., Filipiak-Pittroff, B., Berdel, D., Bauer, C.P., Reinhardt, D., Heinrich, J., Wichmann, H.E., Effect of breastfeeding on the development of atopic dermatitis during the first 3 years of life: results from the GINI birth cohort study. J. Pediatr. 144 (2004), 602–607.
54. [56] Rawlings, A.V., Canestrari, D.A., Dobkowski, B., Moisturizer technology versus clinical performance. Dermatol. Ther. 17 (2004), 49–56.
55. [57] Breternitz, M., Kowatzki, D., Langenauer, M., Elsner, P., Fluhr, J.W., Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol. Physiol. 21 (2008), 39–45.
56. [58] Peris, K., Valeri, P., Altobelli, E., Fargnoli, M.C., Carrozzo, A.M., Chimenti, S., Efficacy evaluation of an oil-in-water emulsion (Dermoflan) in atopic dermatitis. Acta Derm. Venereol. 82 (2002), 465–466.
57. [59] Verallo-Rowell, V.M., Dillague, K.M., Syah-Tjundawan, B.S., Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis 19 (2008), 308–315.
58. [60] Grimalt, R., Mengeaud, V., Cambazard, F., The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 214 (2007), 61–67.
59. [61] Tan, W.P., Suresh, S., Tey, H.L., Chiam, L.Y., Goon, A.T., A randomized double-blind controlled trial to compare a triclosan containing emollient with vehicle for the treatment of atopic dermatitis. Clin. Exp. Dermatol. 35 (2010), e109–e112.
60. [62] Msika, P., De Belilovsky, C., Piccardi, N., Chebassier, N., Baudouin, C., Chadoutaud, B., New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr. Dermatol. 25 (2008), 606–612.
61. [63] Simpson, E.L., Berry, T.M., Brown, P.A., Hanifin, J.M., A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J. Am. Acad. Dermatol. 63 (2010), 587–593.
62. [64] Dabade, T.S., Davis, D.M., Wetter, D.A., Hand, J.L., McEvoy, M.T., Pittelkow, M.R., el-Azhary, R.A., Davis, M.D., Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J. Am. Acad. Dermatol. 67 (2012), 100–106.
63. [65] Devillers, A.C., Oranje, A.P., Efficacy and safety of wet-wrap dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br. J. Dermatol. 154 (2006), 579–585.
64. [66] Schnopp, C., Holtmann, C., Stock, S., Remling, R., Fölster-Holst, R., Ring, J., Abeck, D., Topical steroids under wet-wrap dressings in atopic dermatitis-a vehicle-controlled trial. Dermatology 204 (2002), 56–59.
65. [67] Hanifin, J., Gupta, A.K., Rajagopalan, R., Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br. J. Dermatol. 147:3 (2002), 528–537.
66. [68] Nuutinen, P., Riekki, R., Parikka, M., Salo, T., Autio, P., Risteli, J., Oikarinen, A., Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br. J. Dermatol. 148:1 (2003), 39–45.
67. [69] Peserico, A., Städtler, G., Sebastian, M., Fernandez, R.S., Vick, K., Bieber, T., Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br. J Dermatol. 158:4 (2008), 801–807.
68. [70] Glazenburg, E.J., Wolkerstorfer, A., Gerretsen, A.L., Mulder, P.G., Oranje, A.P., Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls?. Pediatr. Allergy Immunol. 20:1 (2009), 59–66.
69. [71] Nelson, A.A., Miller, A.D., Fleischer, A.B., Balkrishnan, R., Feldman, S.R., How much of a topical agent should be prescribed for children of different sizes?. J. Dermatol. Treat. 17 (2006), 224–228.
70. [72] Thomas, K.S., Armstrong, S., Avery, A., Po, A.L., O'Neill, C., Young, S., Williams, H.C., Randomized controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. Br. Med. J., 324, 2002, 768.
71. [73] Callen, J., Chamlin, S., Eichenfield, L.F., Ellis, C., Girardi, M., Goldfarb, M., Hanifin, J., Lee, P., Margolis, D., Paller, A.S., Piacquadio, D., Peterson, W., Kaulback, K., Fennerty, M., Wintroub, B.U., A systematic review of the safety of topical therapies for atopic dermatitis. Br. J. Dermatol. 156 (2007), 203–221.
72. [74] Breuer, K., Werfel, T., Kapp, A., Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am. J. Clin. Dermatol. 6 (2005), 65–77.
73. [75] Boguniewicz, M., Fiedler, V.C., Raimer, S., Lawrence, I.D., Leung, D.Y., Hanifin, J.M., A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children: pediatric tacrolimus study group. J. Allergy Clin. Immunol. 102 (1998), 637–644.
74. [76] Eichenfield, L.F., Lucky, A.W., Boguniewicz, M., Langley, R.G., Cherill, R., Marshall, K., Bush, C., Graeber, M., Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol. 46 (2002), 495–504.
75. [77] Ho, V.C., Gupta, A., Kaufmann, R., Todd, G., Vanaclocha, F., Takaoka, R., Fölster-Holst, R., Potter, P., Marshall, K., Thurston, M., Bush, C., Cherill, R., Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J. Pediatr. 142 (2003), 155–162.
76. [78] Kang, S., Lucky, A.W., Pariser, D., Lawrence, I., Hanifin, J.M., Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J. Am. Acad. Dermatol. 44 (2001), S58–S64.
77. [79] El-Batawy, M.M., Bosseila, M.A., Mashaly, H.M., Hafez, V.S., Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J. Dermatol. Sci. 54 (2009), 76–87.
78. [80] Murrell, D.F., Calvieri, S., Ortonne, J.P., Ho, V.C., Weise-Riccardi, S., Barbier, N., Paul, C.F., A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br. J. Dermatol. 157 (2007), 954–959.
79. [81] Draelos, Z.D., Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr. Med. Res. Opin. 24 (2008), 985–994.
80. [82] Lübbe, J., Friedlander, S.F., Cribier, B., Morren, M.A., García-Díez, A., Gelmetti, C., Hofmann, H., Houwing, R.H., Kownacki, S., Langley, R.G., Virtanen, M., Wolff, K., Wisseh, S., McGeown, C., Abrams, B., Schneider, D., Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am. J. Clin. Dermatol. 7 (2006), 121–131.
81. [83] Zuberbier, T., Brautigam, M., Long-term management of facial atopic eczema with pimecrolimus cream 1% in pediatric patients with mild to moderate disease. J. Eur. Acad. Dermatol. Venereol. 22 (2008), 718–721.
82. [84] Doss, N., Reitamo, S., Dubertret, L., Fekete, G.L., Kamoun, M.R., Lahfa, M., Ortonne, J.P., Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br. J. Dermatol. 161 (2009), 427–434.
83. [85] Huang, J.T., Rademaker, A., Paller, A.S., Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Arch. Dermatol. 147:2 (2011), 246–247.
84. [86] Huang, J.T., Abrams, M., Tlougan, B., Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 123 (2009), e808–e814.
85. [87] Bath-Hextall, F.J., Birnie, A.J., Ravenscroft, J.C., Williams, H.C., Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br. J. Dermatol. 163 (2010), 12–26.
86. [88] Valkova, S., Velkova, A., UVA/UVB phototherapy for atopic dermatitis revisited. J. Dermatol. Treat. 15:4 (2004), 239–244.
87. [89] Grundmann-Kollmann, M., Ludwig, R., Zollner, T.M., Ochsendorf, F., Thaci, D., Boehncke, W.H., Krutmann, J., Kaufmann, R., Podda, M., Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. J. Am. Acad. Dermatol. 50:5 (2004), 734–739.
88. [90] Tzaneva, S., Seeber, A., Schwaiger, M., Hönigsmann, H., Tanew, A., High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J. Am. Acad. Dermatol. 45:4 (2001), 503–507.
89. [91] Dittmar, H.C., Pflieger, D., Schöpf, E., Simon, J.C., [UVA1 phototherapy: pilot study of dose finding in acute exacerbated atopic dermatitis]. Hautarzt 52:5 (2001), 423–427.
90. [92] Meduri, N.B., Vandergriff, T., Rasmussen, H., Jacobe, H., Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol. Photoimmunol. Photomed. 23:4 (2007), 106–112.
91. [93] Berberian, B.J., Breneman, D.L., Drake, L.A., Gratton, D., Raimir, S.S., Phillips, S., Sulica, V.I., Bernstein, J.E., The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis. Int. J. Dermatol. 38 (1999), 145–148.
92. [94] Bonnel, R.A., La Grenade, L., Karwoski, C.B., Beitz, J.G., Allergic contact dermatitis from topical doxepin: food and drug administration's postmarketing surveillance experience. J. Am. Acad. Dermatol. 48 (2003), 294–296.
93. [95] Jensen, A.M., Lladó, M.B., Skov, L., Hansen, E.R., Larsen, J.K., Baadsgaard, O., Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br. J. Dermatol. 139:6 (1998), 984–991.
94. [96] Nagpal, S., Lu, J., Boehm, M.F., Vitamin D analogs: mechanism of action and therapeutic applications. Curr. Med. Chem. 8:13 (2001), 1661–1679.
95. [97] Schmitt, J., Schmitt, N., Meurer, M., Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venerol. 21:5 (2007), 606–619.
96. [98] Lee, S.S., Tan, A.W., Giam, Y.C., Cyclosporin in the treatment of severe atopic dermatitis: a retrospective study. Ann. Acad. Med. Singapore 33:3 (2004), 311–313.
97. [99] Harper, J.I., Ahmed, I., Barclay, G., Lacour, M., Hoeger, P., Cork, M.J., Finlay, A.Y., Wilson, N.J., Graham-Brown, R.A., Sowden, J.M., Beard, A.L., Sumner, M.J., Berth-Jones, J., Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br. J. Dermatol. 142:1 (2000), 52–58.
98. [100] Hughes, R., Collins, P., Rogers, S., Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin. Exp. Dermatol. 33:6 (2008), 710–711.
99. [101] Berth-Jones, J., Takwale, A., Tan, E., Barclay, G., Agarwal, S., Ahmed, I., Hotchkiss, K., Graham-Brown, R.A., Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br. J. Dermatol. 147:2 (2002), 324–330.
100. [102] Kuanprasert, N., Herbert, O., Barnetson, R.S., Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas. J. Dermatol. 43:2 (2002), 125–127.
101. [103] Hon, K.L., Ching, G.K., Leung, T.F., Chow, C.M., Lee, K.K., Ng, P.C., Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J. Dermatol. Treat. 20:3 (2009), 141–145.
102. [104] Jang, I.G., Yang, J.K., Lee, H.J., Yi, J.Y., Kim, H.O., Kim, C.W., Kim, T.Y., Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J. Am. Acad. Dermatol. 42:6 (2000), 1033–1040.
103. [105] Chang, T.T., Stevens, S.R., Atopic dermatitis: the role of recombinant interferon-gamma therapy. Am. J. Clin. Dermatol. 3:3 (2002), 175–183.
104. [106] Zoller, L., Ramon, M., Bergman, R., Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr. Med. Assoc. J. 10:6 (2008), 413–414.
105. [107] Goujon, C., Bérard, F., Dahel, K., Guillot, I., Hennino, A., Nosbaum, A., Saad, N., Nicolas, J.F., Methotrexate for the treatment of adult atopic dermatitis. Eur. J. Dermatol. 16:2 (2006), 155–158.
106. [108] Lyakhovitsky, A., Barzilai, A., Heyman, R., Baum, S., Amichai, B., Solomon, M., Shpiro, D., Trau, H., Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J. Eur. Acad. Dermatol. Venereol. 24:1 (2010), 43–49.
107. [109] Weatherhead, S.C., Wahie, S., Reynolds, N.J., Meggitt, S.J., An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br. J. Dermatol. 156:2 (2007), 346–351.
108. [110] Kikwai, L., Babu, R.J., Prado, R., Kolot, A., Armstrong, C.A., Ansel, J.C., Singh, M., In vitro and in vivo evaluation of topical formulations of spantide II. AAPS PharmSciTech 6 (2005), E565–72.
109. [111] Babu, R.J., Kikwai, L., Jaiani, L.T., Kanikkannan, N., Armstrong, C.A., Ansel, J.C., Singh, M., Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Pharm. Res. 21 (2004), 108–113.
110. [112] Ahmed, T., Preparation of finasteride capsules-loaded drug nanoparticles: formulation, optimization, in vitro, and pharmacokinetic evaluation. Int. J. Nanomed. 11 (2016), 515–527.
111. [113] Wilczewska, A., Niemirowicz, K., Markiewicz, K., Car, H., Nanoparticles as drug delivery systems. Pharmacol. Rep. 64:5 (2012), 1864–1882.
112. [114] Wu, X., Wu, M., Zhao, J.X., Recent development of silica nanoparticles as delivery vectors for cancer imaging and therapy. Nanomedicine 10:2 (2014), 297–312.
113. [115] Salata, O., Applications of nanoparticles in biology and medicine. J. Nanobiotechnology, 2(1), 2004, 3.
114. [116] Rancan, F., Blume-Peytavi, U., Utilization of biodegradable polymeric materials as delivery agents in dermatology. Clin. Cosmet. Invest. Dermatol. 7 (2014), 23–34.
115. [117] El-Say, K.M., Ahmed, T.A., Badr-Eldin, S.M., Fahmy, U., Aldawsari, H., Ahmed, O.A.A., Enhanced permeation parameters of optimized nanostructured simvastatin transdermal films: ex vivo and in vivo evaluation. Pharm. Dev. Technol. 20:8 (2015), 919–926.
116. [118] Kurakula, M., Ahmed, O.A.A., Fahmy, U.A., Ahmed, T.A., Solid lipid nanoparticles for transdermal delivery of avanafil: optimization, formulation, in-vitro and ex-vivo studies. J. Liposome Res. Inf. Healthcare U. S. A. Inc. 00:00 (2016), 1–9.
117. [119] Ahmed, T.A., Aljaeid, B.M., Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des. Dev. Ther. 10 (2016), 483–507.
118. [120] Dubey, V., Mishra, D., Dutta, T., Nahar, M., Saraf, D.K., Jain, N.K., Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J. Control. Release 123:2 (2007), 148–154.
119. [121] Zhang, L.W., MonteiroRiviere, N.A., Assessment of quantum dot penetration into intact, tapestripped, abraded and flexed rat skin. Skin Pharmacol. Physiol. 21:3 (2008), 166–180.
120. [122] Prow, T.W., MonteiroRiviere, N.A., Inman, A.O., et al. Quantum dot penetration into viable human skin. Nanotoxicology 6:2 (2012), 173–185.
121. [123] Lane, M.E., Skin penetration enhancers. Int. J. Pharm. 447:1–2 (2013), 12–21.
122. [124] Prausnitz, M.R., Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 56:5 (2004), 581–587.
123. [125] Lin, L.L., Grice, J.E., Butler, M.K., et al. Time correlated single photon counting for simultaneous monitoring of zinc oxide nanoparticles and NAD(P)H in intact and barrierdisrupted volunteer skin. Pharm. Res. 28:11 (2011), 2920–2930.
124. [126] Shah, P.P., Desai, P.R., Patel, A.R., Singh, M.S., Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Biomaterials 33:5 (2012), 1607–1617.
125. [128] Abdel Mottaleb, M.M., Moulari, B., Beduneau, A., Pellequer, Y., Lamprecht, A., Nanoparticles enhance therapeutic outcome in inflamed skin therapy. Eur. J. Pharm. Biopharm. 82:1 (2012), 151–157.
126. [129] Rodriguez, M.A., Pytlik, R., Kozak, T., et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer 115:15 (2009), 3475–3482.
127. [130] Yarmolenko, P.S., Zhao, Y., Landon, C., et al. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int. J. Hyperthermia 26:5 (2010), 485–498.
128. [131] Pal, A., Khan, S., Wang, Y.F., et al. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res. 25:1A (2005), 331–341.
129. [132] Dragovich, T., Mendelson, D., Kurtin, S., Richardson, K., Von Hoff, D., Hoos, A., A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother. Pharmacol. 58:6 (2006), 759–764.
130. [133] Mross, K., Niemann, B., Massing, U., et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother. Pharmacol. 54:6 (2004), 514–524.
131. [134] Kim, S.T., Lee, K.M., Park, H.J., Jin, S.E., Ahn, W.S., Kim, C.K., Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. J. Gene Med. 11:1 (2009), 26–37.
132. [135] Verma, D.D., Verma, S., Blume, G., Liposomes increase skin penetration of entrapped and non-entrapped hydrophilic substances into human skin: a skin penetration and confocal laser scanning microscopy study. Eur. J. Pharm. Biopharm. 55:3 (2003), 271–277.
133. [136] Honeywell-Nguyen, P.L., Bouwstra, J.A., Vesicles as a tool for transdermal and dermal delivery. Drug Discov. Today: Technol. 2:1 (2005), 67–74.
134. [137] Korting, H.C., Schafer-Korting, M., Carriers in the topical treatment of skin disease. Schafer-Korting, M., (eds.) Handbook of Experimental Pharmacology, 2010, 437–460.
135. [138] Jung, S.H., Cho, Y.S., Jun, S.S., Koo, J.S., Cheon, H.G., Shin, B.C., Topical application of liposomal cobalamin hydrogel for atopic dermatitis therapy. Pharmazie 66:6 (2011), 430–435.
136. [139] Kang, M.J., Eum, J.Y., Jeong, M.S., Park, S.H., Moon, K.Y., Kang, M.H., Kim, M.S., Choi, S.E., Lee, M.W., Lee do, I., Bang, H., Lee, C.S., Joo, S.S., Li, K., Lee, M.K., Seo, S.J., Choi, Y.W., Tat peptide-admixed elastic liposomal formulation of hirsutenone for the treatment of atopic dermatitis in NC/Nga mice. Int. J. Nanomed. 6 (2011), 2459–2467.
137. [140] Kang, M.J., Eum, J.Y., Park, S.H., Kang, M.H., Park, K.H., Choi, S.E., Lee, M.W., Kang, K.H., Oh, C.H., Choi, Y.W., Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice. Int. J. Pharm. 15 (2010), 198–204.
138. [141] Kang, M.J., Eum, J.Y., Jeong, M.S., Choi, S.E., Park, S.H., Cho, H.I., Cho, C.S., Seo, S.J., Lee, M.W., Choi, Y.W., Facilitated skin permeation of oregonin by elastic liposomal formulations and suppression of atopic dermatitis in NC/Nga mice. Biol. Pharm. Bull. 33:1 (2010), 100–106.
139. [142] Touitou, E., Godin, B., Dayan, N., Weiss, C., Piliponsky, A., Levi-Schaffer, F., Intracellular delivery mediated by an ethosomal carrier. Biomaterials 22:22 (2001), 3053–3059.
140. [143] Friend, D., Catz, P., Heller, J., Transdermal delivery of levonorgestrel I: Alkanols as permeation enhancers in vitro. J. Control. Release 7:3 (1998), 243–250.
141. [144] Berner, B., Mazzenga, G.C., Otte, J.H., Ethanol: water mutually enhanced transdermal therapeutic system II: skin permeation of ethanol and nitroglycerin. J. Pharm. Sci. 78:5 (1999), 402–407.
142. [145] Fang, Y.P., Huang, Y.B., Wu, P.C., Tsai, Y.H., Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behaviour. Eur. J. Pharm. Biopharm. 73:3 (2009), 391–398.
143. [146] Nagi, A., Haj, A.L., Abdullah, R., Tamoxifen drug loading solid lipid nanoparticles prepared by hot high pressure homogenization techniques. Am. J. Pharmacol. Toxicol. 3:3 (2008), 219–224.
144. [147] Bhalekar, M.R., Pokharkar, V., Madgulkar, A., Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 10:1 (2009), 289–296.
145. [148] Pople, P.V., Singh, K.K., Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis. Int. J. Pharm. 398:1–2 (2010), 165–178.
146. [149] Pinaki, R.D., Marepally, S., Patel, A.R., Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J. Control. Release 170 (2013), 51–63.
147. [150] Pardeike, J., Schwabe, K., Müller, R.H., Influence of nanostructured lipid carriers (NLC) on the physical properties of the Cutanova Nanorepair Q10 cream and the in vivo skin hydration effect. Int. J. Pharm. 396 (2010), 166–173.
148. [151] Wissing, S.A., Müller, R.H., The influence of solid lipid nanoparticles on skin hydration and viscoelasticity: in vivo study. Eur. J. Pharm. Biopharm. 56:1 (2003), 67–72.
149. [152] Hussain, A., Samad, A., Singh, S.K., Ahsan, M.N., Haque, M.W., Faruk, A., Ahmed, F.J., Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation. Drug Deliv. 11 (2014), 1–16.
150. [153] Hussain, A., Samad, A., Singh, S.K., Ahsan, M.N., Faruk, A., Ahmed, F.J., Enhanced stability and permeation potential of nanoemulsion containing sefsol-218 oil for topical delivery of amphotericin B. Drug Dev. Ind. Pharm. 41:5 (2015), 780–790.
151. [154] Yilmaz, E., Borchert, H.H., Effect of lipid-containing, positively charged nanoemulsion on skin hydration, elasticity and erythema: an in vivo study. Int. J. Pharm. 307:2 (2006), 232–238.
152. [155] Baspinar, Y., Keck, C.M., Borchert, H.H., Development of a positively charged prednicarbate nanoemulsion. Int. J. Pharm. 383 (2010), 201–208.
153. [156] Alam, M.S., Ali, M.S., Alam, N., In vivo study of clobetasol propionate loaded nanoemulsion for topical application in psoriasis and atopic dermatitis. Drug Invent. Today 5:1 (2013), 8–12.
154. [157] He, W., Guo, X., Zhang, M., Transdermal permeation enhancement of N-trimethyl chitosan for testosterone. Int. J. Pharm. 356 (2008), 82–87.
155. [158] Wu, X., Price, G.J., Guy, R.H., Disposition of nanoparticles and an associated lipophilic permeant following topical application to the skin. Mol. Pharmacol. 6 (2009), 1441–1448.
156. [159] Hussain, Z., Katas, H., Mohd Amin, M.C., Kumolosasi, E., Buang, F., Sahudin, S., Self-assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone/hydroxytyrosol: an ex vivo and in vivo study using an NC/Nga mouse model. Int. J. Pharm. 444 (2013), 109–119.
157. [160] Hussain, Z., Katas, H., Mohd Amin, M.C., Kumolosasi, E., Efficient immuno-modulation of TH1/TH2 biomarkers in 2,4-dinitrofluorobenzene-induced atopic dermatitis: nanocarrier-mediated transcutaneous co-delivery of anti-inflammatory and antioxidant drugs. PLoS One 9:11 (2014), e113–e143.
158. [161] Hussain, Z., Katas, H., Mohd Amin, M.C., Kumolosasi, E., Sahudin, S., Downregulation of immunological mediators in 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions by hydrocortisone-loaded chitosan nanoparticles. Int. J. Nanomed. 9 (2014), 5143–5156.
159. [162] Shah, P.P., Desai, P.R., Singh, M., Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. J. Control. Release 158 (2012), 336–345.
160. [163] Kim, M.H., Seo, J.H., Kim, H.M., Jeong, H.J., Zinc oxide nanoparticles, a novel candidate for the treatment of allergic inflammatory diseases. Eur. J. Pharmacol. 738 (2014), 31–39.
161. [164] Rosado, C., Silva, C., Reis, C.P., Hydrocortisone-loaded poly(ε-caprolactone) nanoparticles for atopic dermatitis treatment. Pharm. Dev. Technol. 18:3 (2013), 710–718.
162. [165] Ference, J.D., Last, A.R., Choosing topical corticosteroids. Am. Fam. Physician 79:2 (2009 15), 135–140.